About me

Address: New York: One Bryant Park, Bank of America Tower, New York, NY 10036-6745

Areas of Focus: International Tax; Investment Management & Transactional Tax; Tax; Emerging Markets Funds Transactions; Energy & Natural Resources Funds; Seeding Transactions; Hedge Funds; Real Estate & Infrastructure Funds; Credit Funds; Royalty Monetization; Institutional Investors; Fund Formation; Fund Manager Transactions; Projects & Energy Transition; Private Equity Transactions; Restructuring & Special Situations Tax; Evergreen Funds

Biography:
Stuart Leblang’s practice includes planning and negotiating domestic and international business transactions, corporate and financial tax counseling and representing clients on tax legislative and policy issues before the U.S. Congress, the U.S. Department of Treasury and other federal agencies. He also focuses on various investment fund matters.
Stuart served as Associate International Tax Counsel at the U.S. Department of Treasury. While there, he was involved in legislative and regulatory developments in the international arena. He initiated and developed a number of international provisions contained in the Taxpayer Relief Act of 1997 and President Clinton’s 1998 Budget Proposals, including those relating to foreign tax credits, passive foreign investment companies, hybrid entities and the taxation of foreign investors. Stuart also participated in a number of negotiations with current and prospective U.S. Treasury partners. He has written and spoken extensively on issues relating to domestic and international tax policy.

Representative Work:
-

Credentials:
Education: J.D., Columbia Law School, 1990; B.A., Cornell University, 1987
Bar Admissions: New York, 1991

Recognitions:
- Who’s Who Legal, Corporate Tax.
- Chambers USA , Tax, 2010-2026.
- The Legal 500 U S, Investment Fund Formation and Management: Private Equity Funds; US Taxes: Non-Contentious.

Affiliations:
-

Insights:
- Akin Advises Pharmakon Advisors on Debt Financing for ARCHIMED’s Up to $1.1 Billion Acquisition of Esperion Therapeutics (July 22, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-advisors-on-debt-financing-for-archimeds-up-to-dollar11-billion-acquisition-of-esperion-therapeutics
- Akin Advises Pharmakon Advisors in $200 Million Term Loan Facility for Kestra Medical Technologies (July 15, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-advisors-in-dollar200-million-term-loan-facility-for-kestra-medical-technologies
- Akin Advises Pharmakon Advisors on CHF 250 Million Term Loan to Idorsia Ltd (June 26, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-advisors-on-chf-250-million-term-loan-to-idorsia-ltd
- Akin Advises Pharmakon Advisors in $500 Million Senior Secured Term Loan to Mineralys Therapeutics (June 11, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-advisors-in-dollar500-million-senior-secured-term-loan-to-mineralys-therapeutics
- Chambers USA 2026 Recognizes Akin Lawyers and Practices  (June 4, 2026): https://www.akingump.com/en/insights/awards-and-accolades/chambers-usa-2026-recognizes-akin-lawyers-and-practices
- Akin Advises Pharmakon in $250 Million Senior Secured Term Loan to Zenas BioPharma (April 2, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-in-dollar250-million-senior-secured-term-loan-to-zenas-biopharma
- Akin Advises Pharmakon in $100 Million Debt Financing for Paratek Pharmaceuticals and Radius Health Combination (March 19, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-in-dollar100-million-debt-financing-for-paratek-pharmaceuticals-and-radius-health-combination
- Akin Advises Pharmakon in $250 Million Term Loan Financing for UroGen Pharma  (March 2, 2026): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-in-dollar250-million-term-loan-financing-for-urogen-pharma
- SEC Charges Credit Fund Adviser Over Principal Transaction Pricing Practices (March 2, 2026): https://www.akingump.com/en/insights/alerts/sec-charges-credit-fund-adviser-over-principal-transaction-pricing-practices
- Fifth Circuit Overrules Tax Court, Providing Major Victory for Limited Partners on Self-Employment Tax (January 26, 2026): https://www.akingump.com/en/insights/alerts/fifth-circuit-overrules-tax-court-providing-major-victory-for-limited-partners-on-self-employment-tax
- New Section 892 Regulations: Action Points for Private Fund Sponsors and Non-U.S. Pension Plan & Sovereign Investors (December 24, 2025): https://www.akingump.com/en/insights/alerts/new-section-892-regulations-action-points-for-private-fund-sponsors-and-non-us-pension-plan-and-sovereign-investors
- Akin Advises Pharmakon in its Up to $500 Million Debt Facility Financing for Valneva SE  (October 8, 2025): https://www.akingump.com/en/insights/press-releases/akin-advises-pharmakon-in-its-up-to-dollar500-million-debt-facility-financing-for-valneva-se